Tofersen Linked to Slow but Positive ALS Outcomes

Pressbee - Medscape :

Watch the post from Tofersen Linked to Slow but Positive ALS Outcomes, Now to the details :

An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.
Medscape Medical News

For more, read the news from the source

Tofersen Linked to Slow but Positive ALS Outcomes

This was the summery for Tofersen Linked to Slow but Positive ALS Outcomes We hope that we have succeeded by sharing the full details of this topic.

Medscape Tofersen Linked to Slow but Positive ALS Outcomes An open-label extension of the phase 3 VALOR trial shows statistically significant benefits for the novel antisense oligonucleotide tofersen in patients with amyotrophic lateral sclerosis.Medscape Medical News

Please note that the original topic has been published and is available on Medscape the editing team at PressBee have verified it and it may have been partially modified or quoted from it. You can read and follow this news or topic from its main source.

( PRESSBEE ) An independent news reader does not assume any liability for the material published in it because it does not express the opinion of the site.